News | July 31, 2021
Zydus Cadila receives approval from USFDA for Fulvestrant Injection
The group now has 320 approvals and has so far filed over 400 ANDAs
The group now has 320 approvals and has so far filed over 400 ANDAs
This marks Glenmark's first synthetic decapeptide injectable approval
As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
The newly approved treatment, SKINVIVE by JUVÉDERM, is now the first and only hyaluronic acid injectable cleared specifically for improving neck appearance
Approval is based on results from the phase 3 OASIS 4 clinical trial
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Broadening access for children & patients with inhibitor-complicated hemophilia
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
Subscribe To Our Newsletter & Stay Updated
